Multimorbidity's research challenges and priorities from a clinical perspective: The case of 'Mr Curran'

European Journal of General Practice

Volumn 20, Issue 2, 2014, Pages 139-147

  Muth, Christiane ^a   Beyer, Martin ^a   Fortin, Martin ^b   Rochon, Justine ^c   Oswald, Frank ^a   Valderas, Jose M ^d   Harder, Sebastian ^e   Glynn, Liam G ^f   Perera, Rafael ^d   Freitag, Michael ^g   Kaspar, Roman ^a   Gensichen, Jochen ^g   Van Den Akker, Marjan ^h,i  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^g JENA UNIVERSITY HOSPITAL   (Germany)

^h MAASTRICHT UNIVERSITY   (Netherlands)

ⁱ UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

General practice; Multimorbidity; Polypharmacy; Process evaluation; Scoping exercise

Indexed keywords

ARTICLE; CLINICAL DECISION MAKING; CLINICAL PHARMACOLOGY; GENERAL PRACTICE; GERONTOLOGY; HEALTH CARE NEED; HOLISTIC CARE; HOSPITALIZATION; HUMAN; MEDICAL RESEARCH; MEDICATION COMPLIANCE; MORBIDITY; MORTALITY; MULTIMORBIDITY; OUTCOME ASSESSMENT; PATIENT CARE; POLYPHARMACY; PRIMARY MEDICAL CARE; QUALITY OF LIFE; CASE REPORT; CHRONIC DISEASE; COMORBIDITY; CONSENSUS DEVELOPMENT; HEALTH CARE QUALITY; MALE; MARRIAGE; METHODOLOGY; MIDDLE AGED; PRIMARY HEALTH CARE;

BIOMEDICAL RESEARCH; CHRONIC DISEASE; COMORBIDITY; GENERAL PRACTICE; HUMANS; MALE; MARRIAGE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POLYPHARMACY; PRIMARY HEALTH CARE; PROCESS ASSESSMENT (HEALTH CARE); RESEARCH DESIGN;

EID: 84901975491     PISSN: 13814788     EISSN: 17511402     Source Type: Journal    
DOI: 10.3109/13814788.2013.839651     Document Type: Article

References (87)

1. Fortin M, Bravo G, Hudon C, Vanasse A, Lapointe L. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med. 2005;3:223-8.
2. Glynn LG, Valderas JM, Healy P, Burke E, Newell J, Gillespie P, et al. The prevalence of multimorbidity in primary care and its effect on health care utilization and cost. Fam Pract. 2011;28:516-23.
3. van den Akker M, Buntinx F, Metsemakers JF, Roos S, Knottnerus JA. Multimorbidity in general practice: Prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol. 1998;51:367-75.
4. Fialova D, Topinkova E, Gambassi G, Finne-Soveri H, Jonsson PV, Carpenter I, et al. Potentially inappropriate medication use among elderly home care patients in Europe. J Am Med Assoc. 2005;293:1348-58.
5. Field TS, Gurwitz JH, Harrold LR, Rothschild J, DeBellis KR, Seger AC, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004;52:1349-54.
6. Kuijpers MA, van Marum RJ, Egberts AC, Jansen PA. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol. 2008;65:130-3.
7. Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54:1516-23.
8. Campbell-Scherer D. Multimorbidity: A challenge for evidence-based medicine. Evid Based Med. 2010;15:165-6.
9. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: Implications for pay for performance. J Am Med Assoc. 2005;294:716-24.
10. Tinetti ME, Bogardus ST, Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004;351:2870-4.
11. Fortin M, Lapointe L, Hudon C, Vanasse A, Ntetu AL, Maltais D. Multimorbidity and quality of life in primary care: A systematic review. Health Qual Life Outcomes. 2004; 2: 51.
12. Fortin M, Bravo G, Hudon C, Lapointe L, Almirall J, Dubois MF, et al. Relationship between multimorbidity and health-related quality of life of patients in primary care. Qual Life Res. 2006; 15:83-91.
13. Fortin M, Bravo G, Hudon C, Lapointe L, Dubois M-F, Almirall J. Psychological distress and multimorbidity in primary care. Ann Fam Med. 2006;4:417-22.
14. Glynn LG, Buckley B, Reddan D, Newell J, Hinde J, Dinneen SF, et al. Multimorbidity and risk among patients with established cardiovascular disease: A cohort study. Br J Gen Pract. 2008;58:488-94.
15. Thorpe KE, Howard DH. The rise in spending among Medicare beneficiaries: The role of chronic disease prevalence and changes in treatment intensity. Health Aff (Millwood). 2006; 25: w378-88.
16. Wolf JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162:2269-76.
17. Heath I, Rubinstein A, Stange KC, van Driel ML. Quality in primary health care: a multidimensional approach to complexity. Br Med J. 2009;338:b1242.
18. Plsek PE, Greenhalgh T. Complexity science: The challenge of complexity in health care. Br Med J. 2001;323:625-8.
19. Bodenheimer TS, Berry-Millett R. Care management of patients with complex health care needs. Synth Proj Res Synth Rep. 2012;pii:52372.
20. Valderas JM, Mercer SW, Fortin M. Research on patients with multiple health conditions: Different constructs, different views, one voice. J Comorbidity. 2011;1:1-3.
21. Arksey H, O'Malley L. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol. 2005;8:19-32.
22. Fortin M, Stewart M, Poitras ME, Almirall J, Maddocks H. A systematic review of prevalence studies on multimorbidity: Toward a more uniform methodology. Ann Fam Med. 2012; 10: 142-51.
23. Valderas JM, Glynn LG, Ferrer-Menduina X, Johnson R, Salisbury C. Multi-morbidity, rule or exception? A systematic review and meta-regression of prevalence studies of multi-morbidity. Fam Med. 2011;43(Suppl. 1). Available at http://www.stfm.org/fmsup/napcrg/fmconferencesupplement.cfm?confid = 135 (accessed 3 June 2013).
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-83.
25. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16:622-6.
26. von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992; 45: 197-203.
27. Freitag M, Quinzler R, Beyer M, Dahlhaus A, Doering A, Freund T, et al. Diagnosenselektion für einen neuen medikationsbasierten. Chronic Disease Score (BMBF-FZ: 01ET1004B). Available at http://www.egms.de/static/en/meetings/ fom2011/11fom095.shtml (accessed 3 June 2013).
28. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7:357-63.
29. van den Akker M, Vos R, Knottnerus JA. In an exploratory prospective study on multimorbidity general and disease-related susceptibility could be distinguished. J Clin Epidemiol. 2006;59:934-9.
30. van Weel C, Schellevis FG. Comorbidity and guidelines: Conflict-ing interests. Lancet 2006; 367: 550-1.
31. Lanzer P, Zuehlke H, Jehle P, Silber RE. Cardiovascular multi-morbidity, emerging coalescence of the integrated panvascular approach. Z Kardiol. 2004;93:259-65.
32. Glynn LG, Reddan D, Newell J, Hinde J, Buckley B, Murphy AW. Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: A West of Ireland community-based cohort study. Nephrol Dial Transplant 2007;22:2586-94.
33. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34.
34. Mather HM, Chaturvedi N, Fuller JH. Mortality and morbidity from diabetes in South Asians and Europeans: 11-year follow-up of the Southall Diabetes Survey, London, UK. Diabet Med. 1998;15:53-9.
35. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998; 21: 69-75.
36. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Cause-specific mortality in a population with diabetes: South Tees Diabetes Mortality Study. Diabetes Care 2002;25:43-8.
37. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-847.
38. Smith SM, Soubhi H, Fortin M, Hudon C, O'Dowd T. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. Cochrane Database of Syst Rev. 2012:CD006560.
39. Heran BS, Chen JM, Ebrahim S, Moxham T, Oldridge N, Rees K et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2011:CD001800.
40. Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, et al. Exercise for preventing and treating osteoporosis in postmeno-pausal women. Cochrane Database Syst Rev. 2011:CD000333.
41. Kanning M, Schlicht W. A bio-psycho-social model of successful aging as shown through the variable ' physical activity'. Eur Rev Aging Phys Act. 2008;5:79-87.
42. Mead GE, Morley W, Campbell P, Greig CA, McMurdo M, Lawlor DA. Exercise for depression. Cochrane Database of Syst Rev. 2009:CD00432009.
43. Harkness E, Macdonald W, Valderas J, Coventry P, Gask L, Bower P. Identifying psychosocial interventions that improve both physical and mental health in patients with diabetes: A systematic review and meta-analysis. Diabetes Care. 2010;33:926-30.
44. Cooper A, O'Flynn N. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: Summary of NICE guidance. Br Med J. 2008;336:1246-8.
45. Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: Rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med. 2009; 6: 101-10.
46. Tsai AC, Morton SC, Mangione CM, Keeler EB. A meta-analysis of interventions to improve care for chronic illnesses. Am J Manag Care 2005;11:478-88.
47. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: Translating evidence into action. Health Aff (Millwood). 2004;20:64-78.
48. Morris RL, Sanders C, Kennedy AP, Rogers A. Shifting priorities in multimorbidity: A longitudinal qualitative study of patient's prioritization of multiple conditions. Chronic Illn. 2011;7:147-61.
49. Freund T, Wensing M, Mahler C, Gensichen J, Erler A, Beyer M, et al. Development of a primary care-based complex care management intervention for chronically ill patients at high risk for hospitalization: A study protocol. Implement Sci. 2010;570.
50. Campbell SE, Seymour DG, Primrose WR, Lynch JE, Dunstan E, Espallargues M, et al. A multi-centre European study of factors affecting the discharge destination of older people admitted to hospital: Analysis of in-hospital data from the ACMEplus project. Age Ageing. 2005;34:467-75.
51. Hanlon JT, Schmader KE, Ruby CM, Weinberger M. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc. 2001;49:209.
52. Thomson LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother. 2007;41:1411-26.
53. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: A prospective analysis of 3695 patient-episodes. PLoS One 2009;4:e4439.
54. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. Br Med J. 2004; 329:15-9.
55. Crooks J. Rational therapeutics in the elderly. J Chronic Dis. 1983;36:59-65.
56. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: ' There's got to be a happy medium'. J Am Med Assoc. 2010;304:1592-601.
57. Vestal RE. Drug use in the elderly: A review of problems and special considerations. Drugs 1978;16:358-82.
58. Vestal RE. Aging and pharmacology. Cancer 1997;80: 1302-10.
59. Schaeffer D, Mueller-Mundt G, Haslbeck J. Bewältigung kom-plexer Medikamentenregime bei chronischen Erkrankungen-Herausforderungen aus Sicht der Gesundheitsprofessionen. Veroeffentlichungsreihe des Instituts für Pflegewissenschaft an der Universität Bielefeld (IPW), P07-134 2007. Avaliable at http://www.uni-bielefeld.de/gesundhw/ag6/downloads/ipw-134.pdf (accessed 3 June 2013).
60. Stevenson FA, Cox K, Britten N, Dundar Y. A systematic review of the research on communication between patients and health care professionals about medicines: The consequences for concordance. Health Expect. 2004;7:235-45.
61. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: The new Medical Research Council guidance. Br Med J. 2008; 337:a1655.
62. Perera R, Heneghan C, Yudkin P. Graphical method for depicting randomised trials of complex interventions. Br Med J. 2007;334:127-9.
63. Yudkin P, Perera R, Glasziou P. Complexity of the intervention, in randomized clinical trials of nonpharmacological treatments. In: Boutron I, Ravaud P, Moher D, editors. Randomized clinical trials of nonpharmacological treatments. Boca Raton: CRC Press; Taylor & Francis Group; 2012. pp. 27-42.
64. Mollenkopf H, Walker A. Quality of life in old age-international and multi-disciplinary perspectives. Social Indicators Research Series, 2007.
65. Lawton MP, Moss M, Hoffman C, Kleban MH, Ruckdeschel K, Winter L. Valuation of life: A concept and a scale. J Aging Health 2001;13:3-31.
66. Meropol NJ, Egleston BL, Buzaglo JS, Benson AB, III, Cegala DJ, Diefenbach MA, et al. Cancer patient preferences for quality and length of life. Cancer. 2008;113:3459-66.
67. Vernooij-Dassen MJ, Osse BH, Schade E, Grol RP. Patient autonomy problems in palliative care: Systematic development and evaluation of a questionnaire. J Pain Symptom Manage. 2005;30:264-70.
68. Hills P, Argyle M. The Oxford happiness questionnaire: A compact scale for the measurement of psychological well-being. Pers Individ Dif. 2002;33:1073-82.
69. Gensichen J, Serras A, Paulitsch MA, Rosemann T, Koenig J, Gerlach FM, et al. The patient assessment of chronic illness care questionnaire: Evaluation in patients with mental disorders in primary care. Community Ment Health J. 2011;47:447-53.
70. Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM. Development and validation of the patient assessment of chronic illness care (PACIC). Med Care. 2005; 43: 436-44.
71. Goetz K, Freund T, Gensichen J, Miksch A, Szecsenyi J, Steinhae-user J. Adaptation and psychometric properties of the PACIC short form. Am J Manag Care 2012;18:e55-60.
72. Hickey A, Barker M, McGee H, O'Boyle C. Measuring health-related quality of life in older patient populations: A review of current approaches. Pharmacoeconomics. 2005; 23:971-93.
73. Power M, Quinn K, Schmidt S. Development of the WHOQOL-old module. Qual Life Res. 2005;14:2197-214.
74. Baltes PB. On the incomplete architecture of human ontogeny. Selection, optimization, and compensation as foundation of developmental theory. Am Psychol. 1997;52:366-80.
75. Lawton MP. Three functions of the residential environment. In: Pastalan L, Cowart M, editors. Lifestyle and housing of older adults: The Florida experience. New York: The Haworth Press; 1989. pp. 39-50.
76. Wahl H-W, Mollenkopf H, Oswald F, Claus C. Environmental aspects of quality of life in old age: Conceptual and empirical issues. In: Mollenkopf H, Walker A, editors. Quality of life in old age-international and multidisciplinary perspectives. Dordrecht: Springer; 2007. pp. 101-22.
77. Wahl H-W, Oswald F. Environmental perspectives on aging. In: Dannefer D, Phillipson, C, editors. International handbook of social gerontology. London: London; 2010. pp. 111-24.
78. Wahl HW, Iwarsson S, Oswald F. Aging well and the environment: Toward an integrative model and research agenda for the future. Gerontologist. 2012;52:306-16.
79. Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45:1045-51.
80. Bregnhoj L, Thirstrup S, Kristensen MB, Bjerrum L, Sonne J. Combined intervention programme reduces inappropriate prescribing in elderly patients exposed to polypharmacy in primary care. Eur J Clin Pharmacol. 2009;65:199-207.
81. Hanlon JT, Weinberger M, Samsa GP, Schmader KE, Uttech KM, Lewis IK, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996; 100: 428-37.
82. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51:1173-82.
83. Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 2002;59:877-83.
84. Emsley R, Dunn G, White IR. Mediation and moderation of treatment effects in randomised controlled trials of complex interventions. Stat Methods Med Res. 2010; 19: 237-70.
85. Kernick D. A theoretical framework for multimorbidity: From complicated to chaotic. Br J Gen Pract. 2012;62:659-62.
86. Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CFB, Marteau T. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998; 2: 1 88.
87. Walker AE, McLeer SK. Small group processes relevant to data monitoring committees in controlled clinical trials: An overview of reviews. Clin Trials 2004; 1: 282-96.